Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PCVX – Vaxcyte, Inc.

Vaxcyte, Inc.
PCVX
$48.34
Name : Vaxcyte, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $6,328,008,704.00
EPSttm : -4.85
finviz dynamic chart for PCVX
Vaxcyte, Inc.
$48.34
0.72%
$0.35

Float Short %

6.77

Margin Of Safety %

Put/Call OI Ratio

1.03

EPS Next Q Diff

0.18

EPS Last/This Y

-1.38

EPS This/Next Y

-0.73

Price

48.34

Target Price

98

Analyst Recom

1.2

Performance Q

52.35

Relative Volume

0.8

Beta

1.27

Ticker: PCVX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20PCVX42.90.3914.717030
2025-10-21PCVX42.340.417.577136
2025-10-22PCVX42.630.420.657193
2025-10-23PCVX41.560.441.507505
2025-10-24PCVX42.220.441.507505
2025-10-27PCVX44.580.440.687517
2025-10-28PCVX44.610.460.048313
2025-10-29PCVX43.50.46999.998361
2025-10-30PCVX44.750.470.148398
2025-10-31PCVX45.30.47999.998402
2025-11-03PCVX42.840.474.398405
2025-11-04PCVX41.330.58111.169330
2025-11-05PCVX40.31.020.2311996
2025-11-06PCVX41.721.002.0012176
2025-11-07PCVX41.661.020.0012058
2025-11-10PCVX42.941.022.1112064
2025-11-11PCVX45.691.020.0012077
2025-11-12PCVX46.131.011.0012098
2025-11-13PCVX45.551.010.1012099
2025-11-14PCVX48.711.0139.5212106
2025-11-17PCVX48.41.030.5012281
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20PCVX42.90-49.3- -4.77
2025-10-21PCVX42.31-49.3- -4.77
2025-10-22PCVX42.51-49.3- -4.77
2025-10-23PCVX41.56-49.3- -4.77
2025-10-24PCVX42.22-49.3- -4.77
2025-10-27PCVX44.61-49.3- -4.77
2025-10-28PCVX44.57-49.3- -4.77
2025-10-29PCVX43.44-49.3- -4.77
2025-10-30PCVX44.75-49.3- -4.77
2025-10-31PCVX45.28-49.3- -4.77
2025-11-03PCVX42.82-49.3- -4.77
2025-11-04PCVX41.31-49.3- -4.77
2025-11-05PCVX40.30-49.3- -4.77
2025-11-06PCVX41.72-49.3- -4.77
2025-11-07PCVX41.65-49.3- -4.77
2025-11-10PCVX42.92-49.3- -4.77
2025-11-11PCVX45.66-38.4- -5.09
2025-11-12PCVX46.12-34.8- -5.18
2025-11-13PCVX45.53-34.8- -5.18
2025-11-14PCVX48.71-34.8- -5.18
2025-11-17PCVX48.34-34.8- -5.18
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20PCVX0.002.808.84
2025-10-21PCVX0.002.808.84
2025-10-22PCVX0.002.808.84
2025-10-23PCVX0.002.808.84
2025-10-24PCVX0.002.808.84
2025-10-27PCVX0.002.967.99
2025-10-28PCVX0.002.967.99
2025-10-29PCVX0.002.967.99
2025-10-30PCVX0.002.967.99
2025-10-31PCVX0.002.967.99
2025-11-03PCVX0.002.677.99
2025-11-04PCVX0.002.677.99
2025-11-05PCVX0.002.677.99
2025-11-06PCVX0.002.677.99
2025-11-07PCVX0.002.677.92
2025-11-10PCVX0.002.357.92
2025-11-11PCVX0.002.357.92
2025-11-12PCVX0.002.356.78
2025-11-13PCVX0.002.356.78
2025-11-14PCVX0.002.356.78
2025-11-17PCVX0.007.496.77
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.56

Avg. EPS Est. Current Quarter

-1.37

Avg. EPS Est. Next Quarter

-1.38

Insider Transactions

Institutional Transactions

7.49

Beta

1.27

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

12

Fair Value

Quality Score

9

Growth Score

18

Sentiment Score

88

Actual DrawDown %

60.1

Max Drawdown 5-Year %

-76.2

Target Price

98

P/E

Forward P/E

PEG

P/S

P/B

2.17

P/Free Cash Flow

EPS

-4.92

Average EPS Est. Cur. Y​

-5.18

EPS Next Y. (Est.)

-5.91

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.8

Return on Equity vs Sector %

-49.7

Return on Equity vs Industry %

-34.7

EPS 1 7Days Diff

-0.5

EPS 1 30Days Diff

-0.41

EBIT Estimation

Vaxcyte, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 414
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
stock quote shares PCVX – Vaxcyte, Inc. Stock Price stock today
news today PCVX – Vaxcyte, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PCVX – Vaxcyte, Inc. yahoo finance google finance
stock history PCVX – Vaxcyte, Inc. invest stock market
stock prices PCVX premarket after hours
ticker PCVX fair value insiders trading